PMGC Holdings (ELAB) Net Cash Flow (2022 - 2026)
PMGC Holdings (ELAB) posted Net Cash Flow of $8.9 million for Q1 2026, up 489.35% sequentially from -$2.3 million in Q4 2025, and up 548.32% YoY from $1.4 million in Q1 2025.
PMGC Holdings (ELAB) Net Cash Flow (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Net Cash Flow for 5 years, with the latest figure at $8.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 548.32% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (up 485.07% YoY) and the FY2025 annual result came in at $1.4 million, up 114.82% from the prior year.
- Net Cash Flow grew to $8.9 million in Q1 2026 per ELAB's latest filing, from -$2.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $8.9 million in Q1 2026 and troughed at -$1.2 billion in Q4 2022.
- A 5-year average of -$82.5 million and a median of -$278040.0 in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow slumped 2082.5% in 2024, then soared 567.43% in 2025.
- Over 5 years, Net Cash Flow stood at -$1.2 billion in 2022, then jumped by 100.25% to $2.8 million in 2023, then slumped by 185.61% to -$2.4 million in 2024, then grew by 5.78% to -$2.3 million in 2025, then surged by 489.35% to $8.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $8.9 million, -$2.3 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | PMGC Holdings | 31.45 Mn | 12.66 Mn | 385,691.00 | 3.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.95 Mn |
| Mar 31, 2026 | 8.95 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 318,125.00 |
| Jun 30, 2025 | 318,125.00 |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | -431,678.00 |
| Sep 30, 2024 | -431,678.00 |
| Jun 30, 2024 | -843,009.00 |
| Jun 30, 2024 | -843,009.00 |
| Mar 31, 2024 | -2.38 Mn |
| Mar 31, 2024 | -2.38 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Dec 31, 2023 | 2.85 Mn |